Germany's Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales, after regulators' concerns about side effects scuttled its ambitions almost seven years ago.